Chronic Liver Disease (CLD)

A 56 year old male with a history of long-term alcohol use presents with progressive abdominal distension, lower limb edema, fatigue, and confusion. Physical examination reveals jaundice, spider angiomas, ascites with shifting dullness, and asterixis. Laboratory investigations show elevated bilirubin, prolonged INR, low albumin, and thrombocytopenia. Ultrasound demonstrates a nodular liver with splenomegaly and ascites. Diagnosis?

Diagnosis is decompensated cirrhosis due to chronic liver disease.

1. Definition

Chronic liver disease is progressive liver injury lasting >6 months resulting in fibrosis and eventual cirrhosis.

Cirrhosis is characterized by:

1. Irreversible fibrosis
2. Regenerative nodules
3. Distorted hepatic architecture

Compensated cirrhosis may have normal or mildly abnormal liver enzymes.

2. Etiology

2.1 Common Causes

1. Alcohol-associated liver disease
2. Metabolic dysfunction associated steatotic liver disease (MASLD/MASH)
3. Chronic hepatitis B
4. Chronic hepatitis C

Alcohol-associated liver disease is one of the most common causes of cirrhosis worldwide

2.2 Other Causes

1. Autoimmune hepatitis
2. Hemochromatosis
3. Wilson disease
4. Alpha-1 antitrypsin deficiency
5. Primary biliary cholangitis (PBC)
6. Primary sclerosing cholangitis (PSC)
7. Budd-Chiari syndrome

3. Pathophysiology

1. Chronic hepatic injury activates stellate cells
2. Excess collagen deposition causes fibrosis
3. Distortion of hepatic vascular architecture develops
4. Increased intrahepatic resistance causes portal hypertension
5. Progressive synthetic dysfunction leads to cirrhosis

4. Compensated vs Decompensated Cirrhosis

Compensated Cirrhosis

1. Often asymptomatic
2. May have normal liver enzymes
3. Preserved hepatic function

Decompensated Cirrhosis

1. Ascites
2. Variceal hemorrhage
3. Hepatic encephalopathy
4. Spontaneous bacterial peritonitis
5. Jaundice
6. Hepatorenal syndrome

Any decompensation warrants hepatology and transplant evaluation

5. Clinical Features

5.1 Constitutional Features

1. Fatigue
2. Weight loss
3. Weakness

5.2 Portal Hypertension Features

1. Ascites
2. Splenomegaly
3. Caput medusae
4. Esophageal varices
5. Rectal varices

Platelets <150,000 may be an early clue due to hypersplenism

5.3 Chronic Liver Disease Stigmata

1. Jaundice
2. Spider angiomas
3. Palmar erythema
4. Gynecomastia
5. Testicular atrophy
6. Muscle wasting

5.4 Hepatic Encephalopathy Features

1. Sleep reversal
2. Confusion
3. Asterixis
4. Coma

6. Diagnosis

6.1 Laboratory Findings

1. Elevated bilirubin
2. Elevated INR
3. Low albumin
4. Thrombocytopenia
5. AST and ALT may normalize in end-stage disease

Albumin and INR best reflect synthetic liver function

6.2 Etiology-Specific Evaluation

Alcohol-Associated Liver Disease

1. AST:ALT approximately 2:1
2. Elevated GGT
3. Macrocytosis
4. AST/ALT usually <500

MASLD/MASH

1. Associated with obesity and metabolic syndrome
2. ALT often exceeds AST early

Autoimmune Hepatitis

1. ANA positive
2. ASMA positive
3. Anti-LKM1 positive
4. Elevated IgG

Hemochromatosis

1. Elevated ferritin
2. Elevated transferrin saturation

Wilson Disease

1. Low ceruloplasmin
2. Elevated urine copper
3. Kayser-Fleischer rings

Primary Biliary Cholangitis

1. Antimitochondrial antibody positive
2. Elevated ALP
3. Pruritus

Primary Sclerosing Cholangitis

1. MRCP shows beading
2. Associated with ulcerative colitis
3. Increased cholangiocarcinoma risk

7. Imaging

RUQ Ultrasound with Doppler

1. Best initial imaging
2. Detects nodularity
3. Detects ascites
4. Evaluates thrombosis

Transient Elastography (FibroScan)

1. Preferred noninvasive fibrosis assessment
2. Measures liver stiffness

Liver Biopsy

1. Gold standard when diagnosis remains uncertain
2. Transjugular route preferred with coagulopathy or ascites

8. Major Complications

8.1 Ascites

Most common complication.

Diagnosis

1. New ascites requires diagnostic paracentesis
2. Perform promptly in hospitalized patients

Interpretation

1. SAAG ≥1.1 suggests portal hypertension

Treatment

1. Sodium restriction ≤2 g/day
2. Spironolactone and furosemide
3. Typical starting ratio: 100:40
4. Avoid NSAIDs and ACE inhibitors/ARBs in decompensated disease

8.2 Spontaneous Bacterial Peritonitis (SBP)

Diagnosis

1. Ascitic PMN ≥250 cells/µL

Common Organisms

1. Escherichia coli
2. Enteric gram-negative organisms

Treatment

1. Cefotaxime or ceftriaxone
2. Albumin:
• 1.5 g/kg day 1
• 1 g/kg day 3

Prophylaxis

1. TMP-SMX or fluoroquinolone in selected patients

8.3 Esophageal Varices

Acute Variceal Bleeding

1. Secure airway if indicated
2. IV access and resuscitation
3. Start octreotide immediately
4. Start ceftriaxone before endoscopy
5. Urgent upper endoscopy with endoscopic variceal ligation

Restrictive transfusion strategy with target hemoglobin approximately 7 g/dL

Prevention

Primary prophylaxis:

1. Nonselective beta blockers or endoscopic variceal ligation

Secondary prophylaxis:

1. Nonselective beta blockers plus repeated band ligation

TIPS may be required for recurrent bleeding

8.4 Hepatic Encephalopathy

Triggers

1. GI bleeding
2. Infection
3. Constipation
4. Sedatives
5. Hypokalemia
6. Metabolic alkalosis

Treatment

1. Lactulose first-line
2. Titrate to 2 to 4 soft stools daily
3. Add rifaximin for recurrent disease

Ammonia levels correlate poorly with severity

8.5 Hepatorenal Syndrome (HRS-AKI)

Diagnosis

1. AKI despite albumin challenge
2. No shock
3. No nephrotoxins
4. No structural kidney disease

Treatment

1. Albumin
2. Terlipressin preferred where available
3. Norepinephrine in ICU setting
4. Liver transplantation is definitive

9. Hepatocellular Carcinoma (HCC)

Surveillance

1. Liver ultrasound with or without AFP every 6 months
2. AFP alone is insufficient

Continue surveillance even after HCV cure if cirrhosis remains

Diagnosis

1. Multiphasic CT or MRI
2. Arterial enhancement with venous washout

Biopsy is not always required

10. Severity Assessment

Child-Pugh Score

Includes:

1. Bilirubin
2. Albumin
3. INR/PT
4. Ascites
5. Encephalopathy

Class A = compensated disease
Class C = severe disease

MELD-Na Score

Uses:

1. Bilirubin
2. INR
3. Creatinine
4. Sodium

MELD ≥15 warrants transplant evaluation

11. Management

1. Treat underlying cause
2. Avoid alcohol
3. Vaccinate against HAV, HBV, influenza, pneumococcus, and COVID
4. Maintain adequate nutrition with protein intake 1.2–1.5 g/kg/day
5. Avoid NSAIDs, aminoglycosides, and excessive sedatives
6. Acetaminophen may be used cautiously, often ≤2 g/day
7. Early transplant referral when indicated

Routine protein restriction is not recommended

12. Transplant Indications

1. MELD ≥15
2. Decompensated cirrhosis
3. Hepatocellular carcinoma within transplant criteria
4. Hepatorenal syndrome
5. Hepatopulmonary syndrome

Definitive treatment for end-stage cirrhosis is liver transplantation

13. Key Clinical Insight

Patient with ascites, thrombocytopenia, jaundice, encephalopathy, and signs of portal hypertension strongly suggests decompensated cirrhosis

14. Key Exam Points

1. Most common complication is ascites
2. Most dangerous acute complication is variceal hemorrhage
3. New ascites requires diagnostic paracentesis
4. Lactulose is first-line for hepatic encephalopathy
5. SBP is diagnosed with PMN ≥250 cells/µL
6. Ultrasound with or without AFP every 6 months for HCC surveillance
7. MELD-Na guides transplant allocation
8. Protein restriction is outdated and not routinely recommended
9. Cirrhosis may have normal AST/ALT in late disease
10. Liver transplantation is definitive treatment for end-stage cirrhosis